MarginsXMarginsX
Home › Markets › Health Care › PHIO

Phio Pharmaceuticals Corp. (PHIO)

PHIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7522
-2.44% on the day
Market cap
$9.0M
Nano cap
Revenue · 2020
$0
-100.0% on 2019
Net income · 2020
-$8.8M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/0001683168-21-001062-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerPHIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001533040
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2020

LineValue
Revenue$0
Net income-$8.8M
Operating income-$8.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$14.3M
Total assets$15.7M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
10.3 months
$10.6M cash at September 30, 2026
Share count, 1 year
+11.0%
2025-11-11 to 2026-11-03 · +4302.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$91K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt regarding the Company's ability to continue as a going concern."
10-Q 2026-11-05
Cash and burn$10.6M cash; operating cash flow -$3.1M a quarter.Report 2026-09-30
Shares outstanding11,951,632 (2026-11-03); 10,764,428 a year earlier; 2,443,447 three years earlier. 3y figure adjusted for splits (1-for-9 overall).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-9 on 2024-07-05Source 2024-07-05
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-08
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $91K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$4.2M-$2.3M$10.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$4.1M-$4.0M$13.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$4.0M-$4.0M$17.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$2.4M-$2.1M$21.0MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$2.4M-$2.1M$10.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$2.2M-$2.5M$10.8MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$1.8M-$1.3M$13.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$1.6M-$1.4M$5.4MNo debt tagsNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52026-04-08
Latest annual report
FORM 10-K
10-K2026-03-05
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxy
ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
DEFA14A2026-08-14

Source: SEC EDGAR submissions feed, 899 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.7%
1 month-17.5%
3 months-29.3%
Year to date-26.6%
1 year-46.1%
From 52-week high-53.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BFRGBullfrog AI Holdings Inc.$0.4878-9.92%$9.0M
GDTCCytoMed Therapeutics Limited$0.7739-6.68%$9.2M
LEXXLexaria Bioscience Corp.$4.41-0.68%$9.3M
VTGNVistagen Therapeutics Inc.$0.1843+2.11%$8.5M
CALCCalciMedica Inc.$1.19-1.65%$8.2M
MTVAMetaVia Inc.$1.21-7.31%$8.1M
AEONAEON Biopharma Inc.$0.1407-8.04%$10.1M
RKTORocket One Inc.$0.3210+0.03%$8.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier